GITAM student builds heart-attack detector

GITAM Deemed to be University said on May 23 that its PhD scholar Konda Venkata Sai has developed a portable device aimed at detecting early heart-attack risk. The university’s official X account linked the project to Sai’s selection for the Prime Minister’s Fellowship for Doctoral Research, a program backed by the Anusandhan National Research Foundation and the Confederation of Indian Industry. External reports published in April identified the device as “MyoTrack” and described it as a low-cost cardiac biosensor under development. ### Who is Konda Venkata Sai, and what has GITAM said he built? Konda Venkata Sai is a research scholar at GITAM’s School of Science in Visakhapatnam, according to April reports and the fellowship selection list. ETV Bharat reported on April 25 that Sai was developing “MyoTrack,” a portable device designed to detect early signs of a heart attack, while GITAM’s May 23 social-media post said the device was meant for early heart-attack risk screening. (etvbharat.com) The Hans India reported on April 27 that Sai described MyoTrack as a “next generation, portable, point-of-care” cardiac biosensor. That report said the device was being designed to analyze a small blood sample and measure multiple biomarkers rather than relying on a single indicator. (etvbharat.com) ### What problem is the device supposed to address? The Hans India reported that Sai said standard triage tools such as ECG and troponin testing can miss some patients during an early diagnostic window. The report quoted him as saying patients may show normal ECG and troponin results even when other markers point to plaque instability or early cardiac stress. (thehansindia.com) ETV Bharat reported that Sai said the goal was to enable earlier detection before a full cardiac event occurs. That report said the device was being designed for ambulances, rural health centers and primary-care clinics, where access to advanced laboratory infrastructure can be limited. ### How does MyoTrack differ from conventional testing, based on available reporting? (thehansindia.com) The Hans India said MyoTrack is being developed as a serum-based diagnostic platform that combines troponin with other early-risk cardiac biomarkers. The report said Sai described the system as using electrochemical sensing and AI/ML software to generate a patient risk score from a single rapid test. (etvbharat.com) April coverage did not include published clinical-trial results, regulatory clearance or commercialization timelines. The available reporting describes the device as a research-stage project under development rather than a product already in routine medical use. That is an inference from the April reports’ wording and the fellowship-stage status. (thehansindia.com) ### Why is the Prime Minister’s Fellowship part of this story? ANRF-CII’s published selection list shows “Venkata Sai Konda” of GITAM School of Science among candidates recommended to receive the Prime Minister’s Fellowship for Doctoral Research. The same document lists Biomexia Health Care Pvt. Ltd. as the partner company for his project. (etvbharat.com) ETV Bharat reported that Sai was among 51 researchers chosen nationwide and said the fellowship carries a monthly stipend of 90,000 rupees for four years, along with project funding. India’s science portal says the fellowship is intended to support industry-relevant doctoral research in science and technology fields. (primeministerfellowshipscheme.in) ### Who is guiding the work, and what comes next? The Hans India and ETV Bharat both said Sai is working under the guidance of Rahul Kumar, an assistant professor in the department of life sciences at GITAM. Both reports described the project as part of Sai’s doctoral research rather than a completed commercial rollout. (etvbharat.com) GITAM’s May 23 post is the latest public update located for the project. The next verifiable milestones would likely be university disclosures, research publications, prototype validation data, or regulatory filings tied to MyoTrack, Sai, Rahul Kumar or partner company Biomexia Health Care Pvt. Ltd. (primeministerfellowshipscheme.in) (etvbharat.com)